Alaunos Therapeutics Inc. (NASDAQ:TCRT) finished Thursday with a subtraction of $0.0 to close at $0.14, a downside of -1.81 percent. An average of 9,066,228 shares of common stock have been traded in the last five days. There was a gain of $0.0094 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 4,425,182 shares traded, while the 50-day average volume stands at 2,054,975.
TCRT stock has decreased by -69.25% in the last month. The company shares reached their 1-month lowest point of $0.1200 on 08/22/23. With the stock rallying to its 52-week high on 01/17/23, shares of the company touched a low of $0.12 and a high of $4.01 in 52 weeks. It has reached a new high 5 times so far this year and lost -79.06% or -$0.5163 in price. In spite of this, the price is down -96.61% from the 52-week high.
Valuation Metrics
Alaunos Therapeutics Inc. (TCRT) stock’s beta is 0.36. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 12.00, the price-to-book (PB) ratio at 1.51.
Financial Health
The quick ratio of Alaunos Therapeutics Inc. for the three months ended June 29 was 3.70, and the current ratio was 3.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Alaunos Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -1111.53%. Its gross profit as reported stood at $38.03 million compared to revenue of $2.92 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Alaunos Therapeutics Inc.’s return on assets was -70.50%.
Earnings Surprise
The company posted a net income of -$8.77 million in the quarter, while revenues were shrunk -13.23%. The analyst consensus anticipated Alaunos Therapeutics Inc.’s latest quarter earnings to come in at -$0.04 per share, but it turned out to be -$0.04, a 0.00% surprise. For the quarter, EBITDA amounted to -$6.42 million. Shareholders own equity worth $240.63 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Alaunos Therapeutics Inc. (TCRT) price momentum. RSI 9-day as of the close on 24 August was 21.93%, suggesting the stock is oversold, with historical volatility in this time frame at 534.91%.
As of today, TCRT’s price is $0.1372 +7.62% or $0.0094 from its 5-day moving average. TCRT is currently trading -70.09% lower than its 20-day SMA and -78.75% lower than its 100-day SMA. However, the stock’s current price level is -70.74% below the SMA50 and -88.35% below the SMA200.
The stochastic %K and %D were 5.86% and 5.47%, respectively, and the average true range (ATR) was 0.0392. With the 14-day stochastic at 4.05% and the average true range at 0.0399, the RSI (14) stands at 23.18%. The stock has reached 0.0013 on the 9-day MACD Oscillator while the 14-day reading was at -0.0952.
Analyst Ratings
The consensus rating for Alaunos Therapeutics Inc. (TCRT) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TCRT, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is TCRT’s price target for the next 12 months?
Analysts predict a range of price targets between $7.50 and $7.50, with a median target of $7.50. Taking a look at these predictions, the average price target given by analysts for Alaunos Therapeutics Inc. (TCRT) stock is $7.50.
